R. Lai

发表

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.

C. Halldin, L. Farde, J. Matthews, 2006, Brain : a journal of neurology.

Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET

Alan A. Wilson, M. Laruelle, E. Rabiner, 2010, Journal of Nuclear Medicine.

Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double‐blind, placebo‐controlled study

P. Anand, A. Krishen, R. Lai, 2013, European journal of pain.

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

L. Lannfelt, H. Basun, A. Satlin, 2016, Alzheimer's Research & Therapy.

A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel‐Based Morphometry

Thomas E. Nichols, Brandon Whitcher, C. Halldin, 2010, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing

A. Satlin, B. Albala, R. Lai, 2012, Alzheimer's & Dementia.

A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [ 18 F ] FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer ’ s Disease

Thomas E. Nichols, P. Matthews, Brandon Whitcher, 2010 .

A first-in-human study of BAN2401, a novel monoclonal antibody against beta-amyloid protofibrils

L. Lannfelt, B. Navia, A. Satlin, 2013, Alzheimer's & Dementia.

Effects of 12 months of treatment with the PPARγ agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A 18F-FDG PET study

P. Matthews, E. Reiman, E. Rabiner, 2009, Alzheimer's & Dementia.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

D. Berry, J. Cummings, L. Lannfelt, 2020, Alzheimer's Research & Therapy.

The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans

B. Chizh, A. Napolitano, R. Lai, 2007, Pain.

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.

Thomas E. Nichols, P. Matthews, Brandon Whitcher, 2011, Journal of Alzheimer's disease : JAD.

A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying

Thomas E. Nichols, P. Matthews, Brandon Whitcher, 2010 .

Chronic Oral Gabapentin Reduces Elements of Central Sensitization in Human Experimental Hyperalgesia

T. Jensen, B. Chizh, R. Lai, 2004, Anesthesiology.

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

L. Lannfelt, H. Basun, A. Satlin, 2016, Alzheimer's Research & Therapy.

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Biomolecules 2016, 6, 19

C. Harrington, R. Lai, C. Wischik, 2016, Biomolecules.

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease

C. Harrington, R. Lai, C. Wischik, 2016, Biomolecules.

A Randomized, Placebo-controlled Trial of the Analgesic Efficacy and Safety of the p38 MAP Kinase Inhibitor, Losmapimod, in Patients With Neuropathic Pain From Lumbosacral Radiculopathy

P. Anand, A. Krishen, R. Lai, 2015, The Clinical journal of pain.

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

M. Roth, C. Harrington, P. Edwards, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Chapter 2 - Structure, biochemistry and molecular pathogenesis of paired helical filaments in Alzheimer's disease

J. Xuereb, M. Roth, C. Harrington, 1995 .

ELENBECESTAT, A NOVEL BACE INHIBITOR, DEMONSTRATES SIMILAR PHARMACOKINETICS AND TOLERABILITY IN JAPANESE SUBJECTS WITH MULTIPLE DOSINGS

N. Hayata, B. Albala, R. Lai, 2018, Alzheimer's & Dementia.

ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG

J. Ferry, B. Albala, B. Darpo, 2017, Alzheimer's & Dementia.

ELENBECESTAT PHARMACOKINETIC DRUG-DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS

J. Ferry, B. Albala, R. Lai, 2017, Alzheimer's & Dementia.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

D. Hosford, M. Irizarry, R. Lai, 2008, Journal of Alzheimer's disease : JAD.

Examination of phosphorylated tau protein as a PHF-precursor at early stage alzheimer's disease

C. Brayne, E. Paykel, F. Huppert, 1995, Neurobiology of Aging.

Quantitative analysis of tau protein in paired helical filament preparations: Implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease

C. Brayne, E. Paykel, F. Huppert, 1995, Neurobiology of Aging.

TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI-Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE

L. Lannfelt, R. Lai, J. Luthman, 2018, Alzheimer's & Dementia.

Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

R. Lai, S. Ishizaka, M. Matijević, 2018 .

P2-409 A pilot study investigating the effects of rosiglitazone on performance in neuropsychological tests in patients with mild-to-moderate Alzheimer’s disease

J. Semple, W. Riedel, P. Peers, 2006, Alzheimer's & Dementia.